Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (139)	6/30/2003 11:39:18 AM
From: tuck	Read Replies (1) \| Respond to of 510

Good to see another deal in the wake of the settlement of the litigation: >>FREMONT, Calif., June 30 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) announced today that it has established a diagnostic biomarker discovery collaboration with bioMerieux S.A. by which the two companies will work together to discover biomarkers and multi-biomarker panels that may improve the diagnosis and management of colon cancer using Ciphergen's ProteinChip® Technology. Cancers of the colon and rectum are the fourth most commonly diagnosed cancers and rank second among cancer deaths in the United States. The agreement calls for installation of proprietary equipment at bioMerieux's Marcy-l'Etoile, France site and close scientific collaboration with our Biomarker Discovery Center® team. Financial and other terms of the agreement were not disclosed. "We're delighted that bioMerieux is embracing our ProteinChip® technology and calling on Ciphergen's Biomarker Discovery Center expertise to co-develop potential diagnostic tests for colon cancer," commented William E. Rich, President and CEO of Ciphergen. "Early detection and better classification of this disease would improve chances for cure and impact patient management." Christophe Merieux, MD., Vice President and Director of Medical Affairs and Research at bioMerieux, added: "Ciphergen offers an innovative platform for the discovery of new markers. The ease-of use, reproducibility and high throughput of the ProteinChip® technology enables rapid discovery and analyses of differences in proteomic expression profiles." About Ciphergen Ciphergen develops, manufactures and markets a family of ProteinChip® Systems and services for clinical, research and process proteomics applications, as well as a broad range of bioseparations media for protein purification through its BioSepra process chromatography division. ProteinChip Systems and Biomarker Discovery Center® collaborative services enable protein discovery, profiling, characterization and assay development to provide researchers with predictive analysis capabilities and a better understanding of biological functions at the protein level. ProteinChip Systems are enabling tools in the emerging field of protein-based biology research, known as proteomics. Proteomics provides a direct approach to understanding the role of proteins in the biology of disease, monitoring disease progression and evaluating the therapeutic effects and side effects of drugs. Ciphergen believes proteomics will be a major focus of biological research by enhancing the understanding of gene function and the molecular basis of disease. Additional information about Ciphergen can be found at www.ciphergen.com. About bioMerieux As a major player in the field of in vitro infectious disease diagnostics, bioMerieux designs, develops, manufactures and markets reagents and automated instruments for medical analyses, and product quality control in the agri-food, cosmetics and pharmaceutical industries. With sales of 945 million Euros in 2002, bioMerieux ranks as the eighth largest biological diagnostics company world-wide. Over 82% of its activity takes place on an international level. bioMerieux, based at Marcy-l'Etoile, France, employs 5450 people throughout the world, including 1550 people in the US and 2100 in France. Investment in Research and Development represented 13% of bioMerieux's sales in 2002. R&D work focused on: -- the continuous development of existing ranges, in order to adapt them to the biologists' recent needs, -- projects resulting in the commercialisation of innovative products and systems. These research programs will prepare bioMerieux to face changes in the healthcare systems and policies. They are focused on bioMerieux's major strategic sectors: clinical bacteriology and industrial microbiology, immunoassays and molecular diagnostics. In bioMerieux, 950 people are dedicated to this research, distributed among 14 specialized research centers in the United States, Brazil and Europe (Lyon - France / Florence - Italy / Boxtel - Netherlands).<< snip Cheers, Tuck